Dianthus Therapeutics

The lean times in biotech financing look set to continue into 2024, with the greatest hope for improvement coming from increased M&A and deal-making activity. That is according to a new survey of 600

Jason Gardner is just a month into his role as CEO of Ampersand Biomedicines , one of the latest companies to emerge from Flagship Pioneering , but is nevertheless confident it can deliver a “new pa

After a month and a half initial public offering drought, two biopharmaceutical companies – Neumora Therapeutics, Inc. and RayzeBio, Inc. – launched IPOs in the US and grossed $561m combined on 14

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Newly Public Dianthus Projects Financia